新活素联合瑞舒伐他汀钙治疗扩张型心肌病心力衰竭的疗效分析

doi:10.3969/j.issn.1006-6233.2023.01.031

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1203 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the efficacy of combination of lyophilized recombinant human brain natriuretic peptide (lrhBNP) and rosuvastatin calcium in treating heart failure (HF) in dilated cardiomyopathy and its influence on cardiac function and levels of serum soluble suppression of tumorigenicity-2 (sST2), recombinant human galectin-3 (Galectin-3) ) and N-pro-brain natriuretic peptide (NT-pro BNP), so as to provide a treatment for this disease. Methods: One hundred and twenty-two patients with dilated cardiomyopathy complicated with HF who were treated in the Third People' s Hospital of Chengdu between October 2018 and October 2021 were enrolled. Random numbers were generated in Microsoft excel using the formula f(x)=rand() and then randomised using the sorting function to produce a randomised summary table, dividing the patients into an observation group (n=61) and a control group (n=61). Both groups were treated with standard basic therapy, with the control group treated with Rosuvastatin calcium in addition to the standard basic therapy and the observation group treated with lrhBNP on top of the control group. The difference in efficacy between the two groups after 7d of treatment was compared, and the differences in cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), stroke volume (SV)] and serum markers (sST2, Galectin-3, NT-pro BNP) were evaluated before treatment and after 7d of treatment. The incidence rates of adverse reactions were analyzed within 7d of treatment. Results: After 7 d of treatment, there was a difference in the overall efficacy between both groups, and the total effective rate of the observation group at 95.08% after treatment was higher than the control group at 83.61% (P<0.05). The LVEF and SV in the two groups were increased after 7 d of treatment compared with those before treatment while the LVEDD, sST2, Galectin-3 and NT-pro BNP were reduced compared to before treatment, and the differences of the above six indicators before and after treatment in observation group were higher compared with those in control group (P<0.05). The incidence rates of adverse reactions within 7 d of treatment showed no statistical differences between the two groups (P>0.05), and there were no serious adverse events in the two groups. Conclusion: LrhBNPcombined with rosuvastatin calcium has a significant efficacy in the treatment of HF in dilated cardiomyopathy, and it has a certain regulatory effect on myocardial remodeling and fibrinolytic system function, with good safety.

Key words： Lrh-BNP Rosuvastatin calcium Dilated cardiomyopathy Heart failure Cardiac function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.01.031 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I1/162

[1] 陈凤梅,鲁星琴,姚亚丽.主动脉弹性与肥厚型心肌病及其心肌纤维化的关系[J].国际心血管病杂志,2020,47(4):207-210.
[2] 袁小媚,王文艳,伍鑫,等.间断重复静脉应用左西孟旦治疗老年扩张型心肌病患者的有效性研究[J].中华老年心脑血管病杂志,2018,20(8):819-822.
[3] Kanukula R,Salam A,Rodgers A,et al.Pharmacokinetics of rosuvastatin:a systematic review of randomised controlled trials in healthy adults[J].Clin Pharmacokinet,2021,60(2):165-175.
[4] Zhang C,Pan S,Aisha A,et al.Recombinant human brain natriuretic peptide regulates PI3K/AKT/mTOR pathway through lncRNA EGOT to attenuate hypoxia-induced injury in H9c2 cardiomyocytes[J].Biochem Biophys Res Commun,2018,503(3):1186-1193.
[5] 刘佳,朱海艳,杨岷,等.新活素对心外科围手术期伴心功能不全患者的疗效和安全性评价[J].药学与临床研究,2019,27(4):286-288,303.
[6] 中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.
[7] Merlo M,Cannata A,Gobbo M,et al.Evolving concepts in dilated cardiomyopathy[J].Eur Heart Fail,2018,20(2):228-239.
[8] Rosenbaum AN,Agre KE,Pereira NL.Genetics of dilated cardiomyopathy:practical implications for heart failure management[J].Nat Rev Cardiol,2020,17(5):286-297.
[9] Boutari C,Karagiannis A,Athyros VG.Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia[J].Expert Rev Cardiovasc Ther,2021,19(7):575-580.
[10] Peng Y,Wei H.Role of recombinant human brain natriuretic peptide combined with sodium nitroprusside in improving quality of life and cardiac function in patients with acute heart failure[J].Exp Ther Med,2020,20(1):261-268.
[11] 王鑫,刘美林,贺少辉,等.重组人脑利钠肽与艾司洛尔联合对缺血性心力衰竭病人临床疗效及血液流变学、血清SOD、MDA水平的影响[J].中西医结合心脑血管病杂志,2018,16(12):1700-1703.
[12] Dong R,Zhang M,Hu Q,et al.Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review)[J].Int Mol Med,2018,41(2):599-614.
[13] Schwinger RHG.Pathophysiology of heart failure[J].Cardiovasc Diagn Ther,2021,11(1):263-276.